nach oben

Pituitary

Erschienen in:

04.11.2019

Prolactinomas and menopause: any changes in management?

verfasst von: Yona Greenman

Erschienen in: Pituitary | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Treatment goals in prolactinomas are to correct hypogonadism, restore fertility and control tumor mass in case of macroadenomas. According to current guidelines, medical treatment of asymptomatic postmenopausal women is not indicated. The purpose of this study was to review the current literature pertaining to biological behavior of prolactinomas during menopause, likelihood of successful dopamine agonist withdrawal during this period and possible prolactin-mediated increased morbidity that could modify current management.

Methods

A comprehensive literature search including papers published until July 2019 was conducted using PubMed and Medline databases.

Results

Women with prolactinomas entering menopause have a higher chance of prolactin normalization of treatment compared with women in their reproductive years. Although most prolactin secreting adenomas diagnosed during menopause are large, they respond well to dopamine agonist treatment. Data directly linking hyperprolactinemia with an increased risk of cancer and cardiovascular and metabolic morbidity are inconsistent. There is no data indicating that correction of hyperprolactinemia improves clinical outcomes in asymptomatic patients bearing microadenomas.

Conclusion

There is no evidence that justifies changing current recommendations to withhold medical treatment of microprolactinomas in asymptomatic post-menopausal women. Macroprolactinoma patients should be treated according to standard clinical practice.

Gruppetta M, Mercieca C, Vassallo J (2013) Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 16:545–553PubMed

Fernandez A, Karavitaki N, Wass JAH (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol 72:377–382

Agustsson TT, Baldvinsdottir T, Jonasson JG, Olafsdottir E, Steinthorsdottir V, Sigurdsson G, Thorsson AV, Carroll PV, Korbonits M, Benediktsson R (2015) The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study. Eur J Endocrinol 173:655–664PubMed

Vroonen L, Daly AF, Beckers A (2019) Epidemiology and management challenges in prolactinomas. Neuroendocrinology 109(1):20–27PubMed

Freeman ME, Kanyicska B, Lerant A, Nagy G (2000) Prolactin: structure, function, and regulation of secretion. Physiol Rev 80(4):1523–1631PubMed

Scheithauer BW, Sano T, Kovacs KT, Young WF Jr, Ryan N, Randall RV (1990) The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin Proc 65(4):461–474PubMed

Kalleinen N, Polo-Kantola P, Irjala K, Porkka-Heiskanen T, Vahlberg T, Virkki A, Polo O (2008) 24-hour serum levels of growth hormone, prolactin, and cortisol in pre- and postmenopausal women: the effect of combined estrogen and progestin treatment. J Clin Endocrinol Metab 93(5):1655–1661PubMed

Cocks Eschler D, Javanmard P, Cox K, Geer EB (2018) Prolactinoma through the female life cycle. Endocrine 59(1):16–29PubMed

Chanson P, Maiter D (2019) The epidemiology, diagnosis and treatment of Prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab 10:101290

10.

Spark RF, Wills CA, O’Reilly G, Ransil BJ, Bergland R (1982) Hyperprolactinaemia in males with and without pituitary macroadenomas. Lancet 2:129–132PubMed

11.

Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68(2):412–418PubMed

12.

Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J (1996) Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 45(3):299–303

13.

Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82(7):2102–2107PubMed

14.

Delgrange E, Vasiljevic A, Wierinckx A, François P, Jouanneau E, Raverot G, Trouillas J (2015) Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. Eur J Endocrinol 172(6):791–801PubMed

15.

Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE (2004) The prevalence of pituitary adenomas: a systematic review. Cancer 101(3):613–619PubMed

16.

Buurman H, Saeger W (2006) Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. Eur J Endocrinol 154:753–758PubMed

17.

Maor Y, Berezin M (1997) Hyperprolactinemia in postmenopausal women. Fertil Steril 67(4):693–696PubMed

18.

Shimon I, Bronstein MD, Shapiro J, Tsvetov G, Benbassat C, Barkan A (2014) Women with prolactinomas presented at the postmenopausal period. Endocrine 47(3):889–894PubMed

19.

Santharam S, Tampourlou M, Arlt W, Ayuk J, Gittoes N, Toogood A, Webster R, Karavitaki N (2017) Prolactinomas diagnosed in the postmenopausal period: clinical phenotype and outcomes. Clin Endocrinol (Oxf) 87(5):508–514

20.

Balint-Perić LA, Prelević GM (1997) Changes in prolactin levels with the menopause: the effects of estrogen/androgen and calcitonin treatment. Gynecol Endocrinol 11(4):275–280PubMed

21.

Reyes FI, Winter JS, Faiman CI (1977) Pituitary-ovarian relationships preceding the menopause. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels. Am J Obstet Gynecol 129(5): 557–564.

22.

Karunakaran S, Page RC, Wass JA (2001) The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 54(3):295–300

23.

Mallea-Gil MS, Manavela M, Alfieri A, Ballarino MC, Chervin A, Danilowicz K, Diez S, Fainstein Day P, García-Basavilbaso N, Glerean M, Guitelman M, Katz D, Loto MG, Martinez M, Miragaya K, Moncet D, Rogozinski AS, Servidio M, Stalldecker G, Vitale M, Boero L (2016) Prolactinomas: evolution after menopause. Arch Endocrinol Metab 60(1):42–46PubMed

24.

Santharam S, Fountas A, Tampourlou M, Arlt W, Ayuk J, Gittoes N, Toogood A, Karavitaki N (2018) Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal. Clin Endocrinol (Oxf) 89(3):346–353

25.

Indirli R, Ferrante E, Sala E, Giavoli C, Mantovani G, Arosio M (2019) Cabergoline withdrawal before and after menopause: outcomes in microprolactinomas. Horm Cancer 10(2–3):120–127PubMed

26.

Chanson P, Maiter D (2019) The epidemiology, diagnosis and treatment of Prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab. https://doi.org/10.1016/j.beem.2019.101290 CrossRef

27.

Dekkers OM, Lagro J, Burman P, Jørgensen JO, Romijn JA, Pereira AM (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 95(1):43–51PubMed

28.

Kloner RA, Carson C 3rd, Dobs A, Kopecky S, Mohler ER 3rd (2016) Testosterone and cardiovascular disease. J Am Coll Cardiol 67(5):545–557PubMed

29.

Santoro N (2011) Update in hyper- and hypogonadotropic amenorrhea. J Clin Endocrinol Metab 96(11):3281–3288PubMed

30.

Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485–534PubMed

31.

Bernard V, Young J, Binart N (2019) Prolactin—a pleiotropic factor in health and disease. Nat Rev Endocrinol 15(6):356–365PubMed

32.

Woodside B (2007) Prolactin and the hyperphagia of lactation. Physiol Behav 91:375–382PubMed

33.

Nielsen JH (2016) Beta cell adaptation in pregnancy: a tribute to Claes Hellerström. Upsala J Med Sci 121(2):151–154PubMedPubMedCentral

34.

Gerardo-Gettens T, Moore BJ, Stern JS, Horwitz BA (1989) Prolactin stimulates food intake in a dose-dependent manner. Am J Physiol 256(1 Pt 2):R276–R280PubMed

35.

Perez Millan MI, Luque GM, Ramirez MC, Noain D, Ornstein AM, Rubinstein M, Becu-Villalobos D (2014) Selective disruption of dopamine D2 receptors in pituitary lactotropes increases body weight and adiposity in female mice. Endocrinology 155:829–839PubMed

36.

Greenman Y, Tordjman Stern N (1998) Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf) 48(5):547–553

37.

Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B, Lombardi G (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148(3):325–331PubMed

38.

Inancli SS, Usluogullari A, Ustu Y, Caner S, Tam AA, Ersoy R, Cakir B (2013) Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma. Endocrine 44:193–199PubMed

39.

Ciresi A, Amato MC, Guarnotta V, Lo Castro F, Giordano C (2013) Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin Endocrinol 79:845–852

40.

Wahlberg J, Tillmar L, Ekman B, Lindahl TL (2013) Effects of prolactin on platelet activation and blood clotting. Scand J Clin Lab Invest 73(3):221–228PubMed

41.

Stuijver DJ, Debeij J, van Zaane B, Dekkers OM, Smit JW, Büller HR, Rosendaal FR, Gerdes VE, Cannegieter SC (2012) Levels of prolactin in relation to coagulation factors and risk of venous thrombosis* Results of a large population-based case-control study (MEGA-study). Thromb Haemost 108(3):499–507PubMed

42.

Faje AT, Klibanski A (2015) The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: cons. Endocrine 48(1):79–82PubMed

43.

Mon SY, Alkabbani A, Hamrahian A, Thorton JN, Kennedy L, Weil R, Olansky L, Doshi K, Makin V, Hatipoglu B (2013) Risk of thromboembolic events in patients with prolactinomas compared with patients with nonfunctional pituitary adenomas. Pituitary 16(4):523–527PubMed

44.

Wang T, Lu J, Xu Y, Li M, Sun J, Zhang J, Xu B, Xu M, Chen Y, Bi Y, Wang W, Ning G (2013) Circulating prolactin associates with diabetes and impaired glucose regulation: a population-based study. Diabetes Care 36(7):1974–1980PubMedPubMedCentral

45.

Li J, Rice MS, Huang T, Hankinson SE, Clevenger CV, Hu FB, Tworoger SS (2018) Circulating prolactin concentrations and risk of type 2 diabetes in US women. Diabetologia 61:2549–2560PubMedPubMedCentral

46.

Therkelsen KE, Abraham TM, Pedley A, Massaro JM, Sutherland P, Hoffmann U, Fox CS (2016) Association between prolactin and incidence of cardiovascular risk factors in the framingham heart study. J Am Heart Assoc 5(2):e002640PubMedPubMedCentral

47.

Reuwer AQ, Twickler MT, Hutten BA, Molema FW, Wareham NJ, Dallinga-Thie GM, Bogorad RL, Goffin V, Smink-Bol M, Kastelein JJ, Boekholdt SM, Khaw KT (2009) Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women. Circ Cardiovasc Genet 2(4):389–395PubMed

48.

Mazziotti G, Porcelli T, Mormando M, De Menis E, Bianchi A, Mejia C, Mancini T, De Marinis L, Giustina A (2011) Vertebral fractures in males with prolactinoma. Endocrine 39(3):288–293PubMed

49.

Mazziotti G, Mancini T, Mormando M, De Menis E, Bianchi A, Doga M, Porcelli T, Vescovi PP, De Marinis L, Giustina A (2011) High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary 14(4):299–306PubMed

50.

Seriwatanachai D, Krishnamra N, van Leeuwen JPTM (2009) Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization. J Cell Biochem 107:677–685PubMed

51.

Klibanski A, Biller BMK, Rosenthal DI, Schoenfeld DA, Saxe V (1988) Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 67(1):124–130PubMed

52.

Clevenger CV, Furth PA, Hankinson SE, Schuler LA (2003) The role of prolactin in mammary carcinoma. Endocr Rev 24:1–27PubMed

53.

Tworoger SS, Eliassen AH, Zhang X, Qian J, Sluss PM, Rosner BA, Hankinson SE (2013) A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res 73(15):4810–4819PubMedPubMedCentral

54.

Wang DY, De Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Fentiman IS, Hayward JL, Millis RR (1992) Relationship of blood prolactin levels and the risk of subsequent breast cancer. Int J Epidemiol 21(2):214–221PubMed

55.

Dekkers OM, Ehrenstein V, Bengtsen M, Kormendine Farkas D, Pereira AM, Sørensen HT, Jørgensen JO (2015) Breast cancer risk in hyperprolactinemia: a population-based cohort study and meta-analysis of the literature. EurJ Endocrinol 173:269–273

56.

Wang M, Wu X, Chai F, Zhang Y, Jiang J (2016) Plasma prolactin and breast cancer risk: a meta-analysis. Sci Rep 6:25998PubMedPubMedCentral

57.

Dekkers OM, Romijn JA, de Boer A, Vandenbroucke JP (2010) The risk for breast cancer is not evidently increased in women with hyperprolactinemia. Pituitary 13:195–198PubMed

58.

Soto-Pedre E, Newey PJ, Bevan JS, Leese GP (2017) Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS study. Endocr Connect 6:580–588PubMedPubMedCentral

59.

Berinder K, Akre O, Granath F, Hulting A (2011) Cancer risk in hyperprolactinemia patients: a population-based cohort study. Eur J Endocrinol 165:209–215PubMed

60.

Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JAH (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:273–288PubMed

Titel: Prolactinomas and menopause: any changes in management?
verfasst von: Yona Greenman
Publikationsdatum: 04.11.2019
Verlag: Springer US
Erschienen in: Pituitary / Ausgabe 1/2020
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-019-00998-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Magnetic resonance imaging in the management of prolactinomas; a review of the evidence

Pathology of prolactinomas: any predictive value?

Prolactinomas in males: any differences?

Dopamine agonist resistant prolactinomas: any alternative medical treatment?

Prolactinomas in pregnancy: considerations before conception and during pregnancy

Biochemical diagnosis in prolactinomas: some caveats